Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Pembrolizumab + Ramucirumab
Indication/Tumor Type lung non-small cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive lung non-small cell carcinoma predicted - sensitive Pembrolizumab + Ramucirumab Phase II Actionable In a Phase II trial (EAST ENERGY), neoadjuvant treatment with Cyramza (ramucirumab) plus Keytruda (pembrolizumab) demonstrated safety and activity in patients with CD274 (PD-L1)-positive (IHC>=1%) non-small cell lung cancer, with a major pathologic response rate of 50.0% (12/24), pathologic complete response rate of 25.0% (6/24), objective response rate of 29.2% (7/24, all partial responses), 2-year overall survival rate of 95.7%, and 2-year relapse-free survival rate of 82.6% (PMID: 39453771; NCT04040361). 39453771
PubMed Id Reference Title Details
(39453771) Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Full reference...